ArticleAnnals of cardiothoracic surgery2012
Malignant pleural mesothelioma: an epidemiological perspective.
Article in Annals of cardiothoracic surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
147 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review.Palliative medicine · 2021Pooled it
- Radical multimodality therapy for malignant pleural mesothelioma.The Cochrane database of systematic reviews · 2018Pooled it
- Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).International journal of clinical oncology · 2016Trial
- Hexokinase II as a Potential Target of Apigenin Through the Induction of Apoptosis and Necroptosis in Malignant Mesothelioma.Nutrients · 2026Article
- Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort study.BMC palliative care · 2026Observational
- Fibroblast-like cells in mesothelioma can derive from tumor cells.Cell death and differentiation · 2026Article
- Review
- Mortality trends of cardiac, mediastinal and pleural malignancies in the United States, 1999-2020: a population-based analysis of demographic and geographic disparities.Frontiers in oncology · 2026Article
- Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China.Translational lung cancer research · 2025Article
- Assessing the impact of waste co-incineration at the Anhovo cement plant (Slovenia) on the regional cancer burden.Radiology and oncology · 2025Article
- CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.Journal of experimental & clinical cancer research : CR · 2025Article
- KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer science · 2025Article
- Titanocenes functionalization with high chemical diversity via titanium protecting groups.Communications chemistry · 2025Article
- Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status.Journal of the Egyptian National Cancer Institute · 2025Article
- Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma.Biomolecules · 2025Review
- Article
- Palliative and end-of-life care for patients with pleural mesothelioma: A cohort study.Palliative medicine · 2025Article
- Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study.Japanese journal of clinical oncology · 2024Article
- Article
- Excision of benign multicystic peritoneal mesothelioma and deep infiltrating endometriosis with bowel involvement - A case report.Case reports in women's health · 2024Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews the aetiology, distribution and projected future incidence of malignant mesothelioma. Asbestos exposure is the most thoroughly established risk factor. Debate continues regarding the relative importance of the different asbestos fibre types and the contribution of Simian virus 40 (SV40). Disease incidence varies markedly within and between countries. The highest annual rates of disease, approximately 30 case per million, are reported in Australia and Great Britain. The risk of disease increases with age and is higher in men. Time from asbestos exposure to disease diagnosis is on average greater than 40 years. Non-occupational asbestos exposures contribute an increasing proportion of disease. With the exception of the United States, incidence continues to increase. In developed countries peak incidence is expected to occur before 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.